We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04072302
Recruitment Status : Completed
First Posted : August 28, 2019
Last Update Posted : August 28, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study is designed to investigate the safety and causal prophylactic efficacy of KAF156 in healthy subjects using a controlled human malaria infection model.

Condition or disease Intervention/treatment Phase
Malaria Drug: KAF156 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 86 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Two-part, Randomized, Double-blind, Placebo-controlled, Single-center Study to Evaluate the Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model
Actual Study Start Date : September 15, 2014
Actual Primary Completion Date : November 29, 2017
Actual Study Completion Date : November 29, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: KAF156 800 mg pre-challenge
Single dose 800 mg KAF156 oral administration in healthy subjects, prior to exposure to P. falciparum sporozoite-infected mosquitos
Drug: KAF156
100 mg tablet, 20 mg tablet, 50 mg tablet

Placebo Comparator: Placebo 800 mg pre-challenge
Single dose 800 mg placebo oral administration in healthy subjects, prior to exposure to P. falciiparum sporozoite-infected mosquitos
Drug: Placebo
100 mg tablet, 20 mg tablet, 50 mg tablet

Experimental: KAF156 800 mg post-challenge
Single dose 800 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: KAF156
100 mg tablet, 20 mg tablet, 50 mg tablet

Placebo Comparator: Placebo 800 mg post-challenge
Single dose 800 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: Placebo
100 mg tablet, 20 mg tablet, 50 mg tablet

Experimental: KAF156 300 mg post-challenge
Single dose 300 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: KAF156
100 mg tablet, 20 mg tablet, 50 mg tablet

Placebo Comparator: Placebo 300 mg post-challenge
Single dose 300 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: Placebo
100 mg tablet, 20 mg tablet, 50 mg tablet

Experimental: KAF156 100 mg post-challenge
Single dose 100 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: KAF156
100 mg tablet, 20 mg tablet, 50 mg tablet

Placebo Comparator: Placebo 100 mg post-challenge
Single dose 100 mg placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: Placebo
100 mg tablet, 20 mg tablet, 50 mg tablet

Experimental: KAF156 20 mg post-challenge
Single dose 20 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: KAF156
100 mg tablet, 20 mg tablet, 50 mg tablet

Placebo Comparator: Placebo 20 mg post-challenge
Single dose 20 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: Placebo
100 mg tablet, 20 mg tablet, 50 mg tablet

Experimental: KAF156 50 mg post-challenge
Single dose 50 mg KAF156 oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: KAF156
100 mg tablet, 20 mg tablet, 50 mg tablet

Placebo Comparator: Placebo 50 mg post-challenge
Single dose 50 mg Placebo oral administration in heatlhy subjects, after exposure to P. falciparum sporozoite-infected mosquitos
Drug: Placebo
100 mg tablet, 20 mg tablet, 50 mg tablet




Primary Outcome Measures :
  1. Number of subjects with parasitemia after single dose oral administration of KAF156 either prior to, or following, exposure to P. falciparum sporozoite-infected mosquitoes [ Time Frame: From Day 1 to Day 43 ]
    The number of subjects that became infected with malaria at each dose

  2. Relationship between pharmacokinetics (i.e., Maximum Plasma Concentration [Cmax], Area Under Curve [AUC]) of KAF156 and number of subjects with parasitemia, after oral administration of single descending doses of KAF156 in healthy subjects with CHMI [ Time Frame: From Day 1 to Day 43 ]
    The exposure-response relationship of KAF156 was explored in a PK/PD model to relate drug exposure to prophylactic efficacy using standard statistical methods such as CART or non-linear regression. Summary statistics were also provided for the malaria incidence rate by cohort and treatment arm


Secondary Outcome Measures :
  1. Number of subjects with adverse events, serious adverse events, and death [ Time Frame: From screening to Day 43 ]
    All information obtained on adverse events will be displayed by arm, treatment, and subject. The number and percentage of subjects with adverse events will be tabulated by body system and preferred term with a breakdown by cohort and treatment.

  2. Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to infinity (AUCinf) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate AUCinf


  3. Pharmacokinetics of KAF156: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate AUClast


  4. Pharmacokinetics of KAF156: Area under teh plasma concentration-time curve from time zero to time 24 h (AUC0-24) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate AUC0-24


  5. Pharmacokinetics of KAF156: Terminal elimination half life (T1/2) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate T1/2.


  6. Pharmacokinetics of KAF156: Apparent systemic clearance from plasma following oral administration (CL/F) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate CL/F


  7. Pharmacokinetics of KAF156: Apparent volume of distribution during the terminal phase following oral administration (Vz/F) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate Vz/F


  8. Pharmacokinetics of KAF156: Observed maximum plasma concentration (Cmax) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate Cmax


  9. Pharmacokinetics of KAF156: Time to reach the maximum concentration (Tmax) [ Time Frame: Pre-dose, and Post-dose: 1 hour, 3 hours, 6 hours, 9 hours, 12 hours, 24 hours, 96 hours, 144 hours, 110 hours, 216 hours, 240 hours ]

    KAF156 plasma concentration data will be listed by arm, subject, and sampling time point.

    Descriptive summary statistics will be provided by arm and sampling time point. These values will be used to calculate Tmax


  10. Parasite growth Kinetics by qRT-PCR [ Time Frame: Pre-dose, days 7-23, Day 29, Day 43 ]
    Parasitemia levels as measured by qRT-PCR will be summarized and displayed graphically over time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

- Healthy male subjects,aged 18 to 40 years of age included and in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests

Exclusion Criteria:

  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
  • Known history or current clinically significant ECG abnormalities or arrhythmias.
  • Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, or other conditions which could interfere with the interpretation of the study results or compromise the health of the subjects.
  • Sexually active males must use a condom during intercourse while taking drug and for al least 4 weeks after stopping study medication and should not father a child during this period.
  • History of malaria or residence in a malaria-endemic area over a period of 6 months before study entry. - Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk or render the subject unable to meet requirements of the protocol.

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04072302


Locations
Layout table for location information
United States, Washington
Novartis Investigative Site
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04072302    
Other Study ID Numbers: CKAF156X2202
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Malaria
KAF156
P. falciparum
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Protozoan Infections
Parasitic Diseases
Infections
Vector Borne Diseases